BioSpace News Archive

QY Research Medical published a comprehensive research on Telomerase Reverse Transcriptase Market, which provides a business strategies, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

According to Vision Research Reports, the ambulatory cardiac monitoring devices market value reached at US$ 13.4 billion in 2020 and projected to surpass around US$ 28.7 billion by 2030.

The global in vitro fertilization test market size is expected to hit around US$ 2.8 billion by 2030 and is expected to grow at a noteworthy CAGR of 6.1% from 2020 to 2030.

According to the report, the interventional pulmonology market size was valued at US$ 3 Bn in 2020 and is expected to reach US$ 8 billion by 2030, expanding growth at a CAGR of 9.1% from 2021 to 2030.

The global intravascular ultrasound devices market size was estimated at US$ 600 million in 2020 and is expected to reach at US$ 1 billion by 2030 with a a CAGR of 6.8% from 2021 to 2030.

The global minimally invasive surgery market was valued at US$ 8.6 Bn in 2020 and is expected to reach US$ 23.4 by 2030.

According to Vision Research Reports, the veterinary teleradiology market reached value at US$ 200 Mn in 2020 and predicted to surpass around US$ 600 million by 2030.

Mersana Therapeutics, Inc. announced that on May 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 104,475 shares of its common stock and restricted stock unit awards to acquire an aggregate of 72,600 shares of its common stock, to 11 new employees whose employment commenced in May 2022.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, announced a grant of stock options to one new employee to purchase 16,000 shares of Assembly Bio common stock with an exercise price of $1.87 per share, the closing price of Assembly Bio’s common stock on June 1, 2022.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) relating to the effect of treatment with aficamten on measures of cardiac structure and function will be presented in a poster presentation at the American Society of Echocardiography (ASE) 33rd Annual Scientific Sessions.